First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors

The oncologist

article

Khanh T. Do¹  Laura Quan Man Chow²  Karen Reckamp³  Rachel E. Sanborn⁴  Howard Burris⁵  Francisco Robert⁶  D. Ross Camidge⁷  Conor E. Steuer⁸  John H. Strickler⁹  Amy Weise^1,10  Jennifer M. Specht²  Martin Gutierrez^1,11  Peter Haughney^1,12  Shawna Hengel^1,12  Christina Louise Derleth^1,12  Timothy A. Yap^1,13 

[1] Dana-Farber Cancer Institute;University of Washington;City of Hope Comprehensive Cancer Center;Earle A. Chiles Research Institute, Providence Cancer Institute;Sarah Cannon Research Institute;University of Alabama at Birmingham, Birmingham, Alabama;University of Colorado Cancer Center;Winship Cancer Institute, Emory University School of Medicine;Duke University Medical Center;Karmanos Cancer Institute, Wayne State University;Hackensack University Medical Center;Seagen Inc.;The University of Texas MD Anderson Cancer Center

关键词: Immunotherapy;    Small molecule agents;    Clinical trials;    Fucosylation inhibitor;    SGN-2FF;   

DOI  :  10.1002/onco.13911

学科分类：地质学

来源: AlphaMed Press Incorporated

【 摘 要 】

Lessons Learned Inhibition of glycoprotein fucosylation, as monotherapy and in combination with immune checkpoint blockade, is a promising therapeutic strategy for treating a broad range of cancers. In this first-in-human, first-in-class, phase I study in advanced solid tumors, SGN-2FF demonstrated dose-proportional pharmacokinetics, evidence of pharmacodynamic target inhibition of glycoprotein fucosylation, and preliminary antitumor activity. SGN-2FF was associated with thromboembolic events that led to study termination.

【 授权许可】

CC BY|CC BY-NC